| Sipuleucel-T immunotherapy for castration-resistant prostate cancer PW Kantoff, CS Higano, ND Shore, ER Berger, EJ Small, DF Penson, ... New England Journal of Medicine 363 (5), 411-422, 2010 | 6642 | 2010 |
| Increased survival with enzalutamide in prostate cancer after chemotherapy HI Scher, K Fizazi, F Saad, ME Taplin, CN Sternberg, K Miller, R De Wit, ... New England Journal of Medicine 367 (13), 1187-1197, 2012 | 5195 | 2012 |
| Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study K Fizazi, M Carducci, M Smith, R Damião, J Brown, L Karsh, P Milecki, ... The Lancet 377 (9768), 813-822, 2011 | 2336 | 2011 |
| Olaparib for metastatic castration-resistant prostate cancer J de Bono, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 382 (22), 2091-2102, 2020 | 1747 | 2020 |
| Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall … CJ Ryan, MR Smith, K Fizazi, F Saad, PFA Mulders, CN Sternberg, ... The Lancet Oncology 16 (2), 152-160, 2015 | 1553 | 2015 |
| Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer M Hussain, K Fizazi, F Saad, P Rathenborg, N Shore, U Ferreira, ... New England Journal of Medicine 378 (26), 2465-2474, 2018 | 1077 | 2018 |
| Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial MR Smith, F Saad, R Coleman, N Shore, K Fizazi, B Tombal, K Miller, ... The Lancet 379 (9810), 39-46, 2012 | 987 | 2012 |
| Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases F Saad, JE Brown, C Van Poznak, T Ibrahim, SM Stemmer, AT Stopeck, ... Annals of oncology 23 (5), 1341-1347, 2012 | 936 | 2012 |
| Darolutamide in nonmetastatic, castration-resistant prostate cancer K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 380 (13), 1235-1246, 2019 | 914 | 2019 |
| ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer AJ Armstrong, RZ Szmulewitz, DP Petrylak, J Holzbeierlein, A Villers, ... Journal of Clinical Oncology 37 (32), 2974, 2019 | 913 | 2019 |
| The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer L Klotz, L Boccon‐Gibod, ND Shore, C Andreou, BE Persson, P Cantor, ... BJU international 102 (11), 1531-1538, 2008 | 802 | 2008 |
| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 592 | 2020 |
| Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018 | 521 | 2018 |
| A multi-institutional prospective trial in the USA confirms that the 4Kscore accurately identifies men with high-grade prostate cancer DJ Parekh, S Punnen, DD Sjoberg, SW Asroff, JL Bailen, JS Cochran, ... European urology 68 (3), 464-470, 2015 | 437 | 2015 |
| Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer CN Sternberg, K Fizazi, F Saad, ND Shore, U De Giorgi, DF Penson, ... New England Journal of Medicine 382 (23), 2197-2206, 2020 | 381 | 2020 |
| Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015 | 380 | 2015 |
| Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020 | 367 | 2020 |
| Oral relugolix for androgen-deprivation therapy in advanced prostate cancer ND Shore, F Saad, MS Cookson, DJ George, DR Saltzstein, R Tutrone, ... New England Journal of Medicine 382 (23), 2187-2196, 2020 | 353 | 2020 |
| Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) DE Rathkopf, MR Smith, JS De Bono, CJ Logothetis, ND Shore, ... European urology 66 (5), 815-825, 2014 | 350 | 2014 |
| Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide K Fizazi, N Shore, TL Tammela, A Ulys, E Vjaters, S Polyakov, M Jievaltas, ... New England Journal of Medicine 383 (11), 1040-1049, 2020 | 331 | 2020 |
